Medmix launches its IPO following Spin-off from Sulzer. The advisors

Following the Spin-off, Sulzer and Medmix shares will start trading separately on the SIX Swiss Exchange. 

In an offering of new shares, which took place at the same time, 7 million new shares were issued in Medmix at CHF 45 per share, raising gross proceeds of CHF 315 million from the capital increase, yielding net proceeds of approximately CHF 295.2 million.  Cred­it Suisse and UBS acted as Joint Glob­al Coordin­at­ors in this transaction. 

The net proceeds will be used to finance organic and inorganic growth initiatives and for general corporate purposes. 

The advisors

Walder Wyss  has advised medmix in this transaction. The team was lead by Urs Schenker  (senior counsel, transactions/m&a, pictured top left) and Dominik Hohler (partner, transactions/ m&a, pictured top right) and further included Theodor Härtsch (partner, transactions/finance), Thomas Meister (partner, tax), Janine Corti (counsel, tax), Daniel Dedeyan (counsel, transactions/finance), Angela Kummer  (associate, transactions/m&a), Etienne Trandafir (associate, transactions/finance) and Thomas Nagel (associate, transactions/ finance).

Advestra acted as leg­al coun­sel to Cred­it Suisse and UBS. The team included Annette Weber (pictured left), Thomas Reut­ter, Fabi­an Loretan and Anna Capaul (all cor­por­ate and cap­it­al mar­kets) and Markus Müh­le­mann (tax). 

For further details about the spin-off click here